{"podcast":{"title":"The NextGen VC Podcast","slug":"the-nextgen-vc-podcast-6617779","podcast_index_feed_id":6617779,"rss_url":"https://anchor.fm/s/e77f3ea0/podcast/rss","website_url":"https://podcasters.spotify.com/pod/show/nextgenvcpodcast","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/38738760/38738760-1693942072183-3e001a56cd566.jpg","author":"LaunchBio","episode_count":24,"summary":"The NextGen VC Podcast is the premier podcast for forward-thinking venture capitalists eager to dive in and sharpen their skills. It unpacks the opportunities, challenges, and breakthroughs shaping life sciences investing today, and is curated by Wilson Sonsini and LaunchBio with hosts Michael Hostetler and Jen Fang. Email the show: questions@launchbio.org Learn about in-person NextGen VC events: launchbio.org/programs/nextgen-vc-forum/ Discover resources for the life sciences community: launchbio.org","last_synced_at":"2026-07-08T02:17:43.433949+00:00","page_url":"https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779"},"episode":{"title":"Why the Future of Biotech Starts With the Brain","slug":"why-the-future-of-biotech-starts-with-the-brain","published_at":"2026-07-07T12:00:00+00:00","page_url":"https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779/why-the-future-of-biotech-starts-with-the-brain","show_page_url":"https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779","url":"https://podcasters.spotify.com/pod/show/nextgenvcpodcast/episodes/Why-the-Future-of-Biotech-Starts-With-the-Brain-e3lmd7h","audio_url":"https://anchor.fm/s/e77f3ea0/podcast/play/122417841/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-6-5%2F427397443-44100-2-5acac227ae3f2.mp3","summary":"What does neuroscience have to do with venture capital? Quite a bit, according to Jason Pitts. In this episode of the NextGen VC podcast, Mike Hostetler and Jen Fang sit down with Jason, Principal at General Atlantic, to talk about the winding path that took him from studying the brain at Cornell to evaluating some of the most promising companies in biotech. Jason shares how a series of unexpected opportunities led him from the lab at Regeneron to McKinsey and ultimately into venture investing. Along the way, he reflects on the mentors, relationships, and career pivots that shaped his journey. The conversation also explores what separates great biotech companies from the rest, why clinical rigor often makes the difference between success and failure, and how investors develop conviction in an industry where uncertainty is part of the territory. Jason also discusses his work with companies like Karuna Therapeutics and explains why advances in neuroscience and brain-shuttle technology could help unlock the next wave of innovation in biotech. Whether you're exploring a career in life sciences, breaking into venture capital, or simply curious about where biotech is headed next, this episode offers an inside look at the science, strategy, and decision-making behind today's most exciting healthcare investments.","meta_description":"What does neuroscience have to do with venture capital? Quite a bit, according to Jason Pitts. In this episode of the NextGen VC podcast, Mike Hostetler a…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2972,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-nextgen-vc-podcast-6617779/episodes/why-the-future-of-biotech-starts-with-the-brain/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779/why-the-future-of-biotech-starts-with-the-brain.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}